Erasca's RAS Inhibitor Data Puts Pressure on Revolution Medicines

Erasca released Phase 1 data for ERAS-0015, a RAS inhibitor that targets the same pathway as Revolution Medicines' daraxonrasib. The results show comparable efficacy at a lower cost, according to the report. That creates a valuation gap between the two stocks.

Erasca's deal with Merck provides funding and development support. Patent risks remain a key overhang. The company's cash runway extends into 2026, based on its latest filing.

The readthrough for Revolution Medicines is straightforward: increased competition could pressure market share and pricing for daraxonrasib. Revolution's Alpha Score sits at 63 out of 100, a Moderate rating in the healthcare sector. The stock page is here.

Erasca's next catalyst is a Phase 2 start for ERAS-0015, expected in the second half of the year.